Cargando…

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors

Activation of Toll-like receptor 9 (TLR9) is known to foster innate and adaptive immune responses and thus improve immune-mediated control of malignant disease. Lefitolimod is a potent TLR9 agonist without chemical modification developed for immunotherapeutic strategies. Modulation of the tumor micr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapp, Kerstin, Volz, Barbara, Oswald, Detlef, Wittig, Burghardt, Baumann, Matthias, Schmidt, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844329/ https://www.ncbi.nlm.nih.gov/pubmed/31741757 http://dx.doi.org/10.1080/2162402X.2019.1659096

Ejemplares similares

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
por: Kapp, Kerstin, et al.
Publicado: (2019)

Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist
por: Volz, Barbara, et al.
Publicado: (2016)

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study
por: Thomas, M, et al.
Publicado: (2018)

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
por: Schmidt, Manuel, et al.
Publicado: (2015)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: Farias, A., et al.
Publicado: (2021)

Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells
por: Shen, Kuan-Yin, et al.
Publicado: (2020)

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
por: Gonzalez, Caleb, et al.
Publicado: (2023)

Genuine Immunomodulation With dSLIM
por: Kapp, Kerstin, et al.
Publicado: (2014)

Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells
por: Kitahata, Yuji, et al.
Publicado: (2016)

Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition
por: Ghosh, Chandra C., et al.
Publicado: (2022)

Intra-Tumoral Activation of Endosomal TLR Pathways Reveals a Distinct Role for TLR3 Agonist Dependent Type-1 Interferons in Shaping the Tumor Immune Microenvironment
por: Thomas, Graham, et al.
Publicado: (2021)

Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
por: Zemek, Rachael M., et al.
Publicado: (2020)

The regulation of immune checkpoints by the hypoxic tumor microenvironment
por: Hu, Min, et al.
Publicado: (2021)

Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity
por: Scharping, Nicole E., et al.
Publicado: (2016)

Cytokine Effect of TLR3, TLR4, and TLR7 Agonists Alone or Associated with Leishmania infantum Antigen on Blood from Dogs
por: Martínez-Orellana, Pamela, et al.
Publicado: (2018)

Contribution of TLR4 to colorectal tumor microenvironment, etiology and prognosis
por: Crame, Elise E., et al.
Publicado: (2022)

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
por: Ohta, Akio
Publicado: (2016)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
por: Xu, Yaolin, et al.
Publicado: (2021)

Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment
por: Heeke, Simon, et al.
Publicado: (2019)

Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
por: Vaupel, Peter, et al.
Publicado: (2016)

Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020)

Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors
por: Li, Zihui, et al.
Publicado: (2020)

Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
por: Talaat, Iman M., et al.
Publicado: (2022)

Checkpoint Markers and Tumor Microenvironment: What Do We Know?
por: Ephraim, Ramya, et al.
Publicado: (2022)

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
por: Mullins, Stefanie R., et al.
Publicado: (2019)

A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment
por: Wei, Cheng-Hsin, et al.
Publicado: (2023)

DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
por: Ota, Yosuke, et al.
Publicado: (2023)

Mode of action of maintenance immunotherapy therapy with the TLR-9 agonist MGN1703 in metastatic colorectal carcinoma: the Phase III IMPALA study
por: Stein, Alexander, et al.
Publicado: (2015)

Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural context
por: Kapp, Kerstin, et al.
Publicado: (2016)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014)

Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands
por: Chew, Valerie, et al.
Publicado: (2013)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Remodeling of the Tumor Microenvironment Through PAK4 Inhibition Sensitizes Tumors to Immune Checkpoint Blockade
por: Abril-Rodriguez, Gabriel, et al.
Publicado: (2022)

An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy
por: Zhang, Huagang, et al.
Publicado: (2012)

Checkpoint blockade‐based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
por: Duan, Jingjing, et al.
Publicado: (2018)

Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
por: Yang, Min, et al.
Publicado: (2020)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
por: Russell, Bonnie L., et al.
Publicado: (2021)

Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
por: Zhou, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o5qfo4i89b119grn9rd1v1n7sr